2016
Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman
Barmettler S, Nowak RJ, Parker T, Price C. Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman. BMJ Case Reports 2016, 2016: bcr2015213698. PMID: 26903364, PMCID: PMC4769444, DOI: 10.1136/bcr-2015-213698.Peer-Reviewed Original ResearchConceptsFamilial haemophagocytic lymphohistiocytosisSoluble CD25 levelHaemophagocytic lymphohistiocytosisCD25 levelsDiagnosis of HLHHigh clinical suspicionInitiation of treatmentIntrathecal chemotherapyClinical suspicionCytotoxic cellsEarly recognitionDiagnostic criteriaPatientsOlder ageHomozygous mutationLymphohistiocytosisWomenCoughPancytopaeniaChemotherapyFeverPerforinMortalitySuspicionDiagnosis
2015
Management of isolated calf vein thrombosis in cancer patients
Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2015, 24: 64-69. PMID: 25957344, DOI: 10.1177/1708538115584726.Peer-Reviewed Original ResearchConceptsCalf vein thrombosisIsolated calf vein thrombosisVein thrombosisHistory of cancerCancer patientsBenefits of anticoagulationInitiation of anticoagulationPatient risk factorsRetrospective chart reviewLong-term recurrenceChart reviewConsecutive patientsTreatment modalitiesRisk factorsThrombosisHigh incidencePatientsAnticoagulationOlder ageCancerMortalityIncidenceAnatomical characteristicsTreatmentRecurrence
2012
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.Peer-Reviewed Original ResearchConceptsAllogeneic PBSC transplantCutaneous toxicityConditioning regimenPBSC transplantsToxic erythemaLow treatment-related mortalityDoses of BUEffective conditioning regimenPalms/solesTreatment-related mortalityEvaluable patientsMost patientsMedian onsetStandard dosesTransplant physiciansClinical presentationScrotal involvementSpecific therapyAllergic reactionsInappropriate treatmentRetrospective analysisHigh incidencePatientsMyeloid neoplasiaBU/
2011
Chronic lymphocytic leukemia: prognostic factors and impact on treatment.
Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11: 115-23. PMID: 21356166.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPrognostic markerBiology of CLLClinical staging systemStandard chemotherapy regimensObvious survival advantageSymptomatic leukemiaChemotherapy regimensMature B cellsPrognostic factorsProlong survivalIndolent diseaseStaging systemClinical managementImmediate treatmentDisease progressionEarly treatmentLymphocytic leukemiaSurvival advantageAggressive formB cellsClinical heterogeneityClonal malignancyEarly interventionPatients